Peptency Academy · Section
Research progress
Dated papers, trial registrations and results, and regulator actions on catalog molecules, each with its source.
Research progressAcademyResearch progress5 pages
Newest first
- Regulator action, 14 Sept 2026TGA laboratory test: a product sold as retatrutide held semaglutideOn 14 Sep 2026 Australia's TGA reported that its laboratory found undeclared semaglutide and no retatrutide in a product sold as retatrutide. Sources inside.
- Trial result, 28 Aug 2026ARISE-3: registry data posted for a thymosin beta 4 trialOn 28 Aug 2026 ClinicalTrials.gov posted outcome data for ARISE-3 (NCT03937882), a phase 3 randomised trial of thymosin beta 4. Design, status, gaps, sources.
- Regulator action, 24 Aug 2026US editionFDA warning letters of 24 Aug 2026 on retatrutide, semaglutide and other peptides sold as research use onlyFive FDA warning letters dated 24 Aug 2026 say research use only statements did not stop peptides sold online being drugs. What the letters cite, with sources.
- Publication, 6 Aug 2026Products sold as retatrutide in Australia: content against the labelA 2026 letter reports identity, content and metals tests on three products sold as retatrutide in Australia. What was measured and what is not known, with sources.
- Publication, 30 Jul 2026Impurity profiles of compounded and follow-on semaglutide: a 2026 LC-MS studyA 2026 Pharmaceutical Research study compared LC-MS impurity profiles of follow-on and compounded semaglutide with the originator. Methods, findings, COI, sources.
Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.